TNF receptor superfamily member 5 (TNFRSF5)

Overview

CD40 is a cell-surface receptor in the tumor necrosis factor receptor superfamily that plays a central role in immune regulation. It is expressed on antigen-presenting cells (APCs) and is a key costimulatory molecule involved in activating adaptive immune responses. When engaged by agonists, CD40 can promote APC maturation and enhance downstream immune signaling, making it an important target in immunotherapy research.

Biologically, CD40 is relevant to both normal immune function and disease-associated inflammation. Because it can amplify immune activation, CD40 has been investigated in cancer, neuroinflammation, and other immune-linked conditions. In therapeutic contexts, CD40 agonism is being explored to strengthen antitumor immunity, although prior clinical experience has also highlighted safety concerns such as hepatotoxicity. Its role therefore sits at the intersection of immune stimulation, inflammatory signaling, and disease modulation.

Recent Publications Focus

Recent work has examined CD40 across both autoimmune and oncology settings. In generalized myasthenia gravis, a Bayesian network meta-analysis of randomized trials included CD40-targeted therapies among several immune-directed approaches and found that, overall, FcRn inhibitors, C5 complement inhibitors, and CD19+ B-cell depletion showed comparable efficacy, while CD40-targeted studies were part of the broader comparative landscape rather than standing out as clearly superior 42467874Jul. In a separate in vitro study of the nondepleting anti-CD40 monoclonal antibody iscalimab, the antibody fully inhibited proliferating B cells and reduced dendritic cell TNF production, but showed limited to no efficacy in suppressing autoreactive effector CD4 T-cell proliferation or naïve alloreactive CD4 T-cell induction, suggesting that CD40 blockade alone may be insufficient for durable benefit in type 1 diabetes or other T cell–mediated diseases 42284279Jun.

Several recent cancer studies have highlighted CD40 signaling as an immune-modulating axis in the tumor microenvironment. Spatial transcriptomics and multiplex imaging in human tumors, together with a mouse non-small cell lung cancer model, showed that CD40 signaling in mature cDC1 dendritic cells helps sustain tertiary lymphoid structures, T follicular helper cell pools, germinal centers, and tumor-specific IgG, supporting local antigen presentation as a key driver of TLS maintenance 42462020Jul. In pancreatic ductal adenocarcinoma, agonistic CD40 antibody therapy prolonged survival in mice, and combining it with IL1R1 blockade enhanced innate and adaptive immune pathways but did not further improve efficacy or reduce liver toxicity; the authors concluded that IL-1R1 blockade should not be advanced with CD40 agonists for this indication 41935073Apr. Another preclinical study developed KK2269, a bispecific antibody targeting Epithelial Cell Adhesion Molecule (EpCAM) and CD40, and found that it selectively activated APCs in the presence of EpCAM-positive cells; KK2269 showed antitumor activity with anti-Programmed cell death 1 (PD-1) antibody, docetaxel, doxorubicin, or oxaliplatin, with docetaxel producing the strongest effect 41989931Apr.

CD40 has also emerged in human genetics and disease association studies. A Mendelian randomization analysis of inflammatory proteins and attention deficit hyperactivity disorder reported that genetically predicted higher CD40 levels were associated with a reduced risk of ADHD, with a possible but non-significant indirect pathway via N-acetylneuraminate 42216364May. In proteome-wide Mendelian randomization across B-cell malignancies, CD40 was identified as a protein associated with Hodgkin lymphoma and was prioritized among candidate therapeutic targets using genetic and single-cell evidence 41859349Mar. In addition, a study of lung cancer patients receiving PD-1 blockade found that B-cell lymphomas arising during therapy showed high expression of CD40, and that PD-1 blockade activated PD-1+ T follicular helper cells that promoted lymphoma proliferation through IL4/IL4R, IL21/IL21R, and CD40L/CD40 axes 42148884May.

Outside oncology and neurodevelopment, CD40 also appeared in host-response analyses of infection. A machine-learning and WGCNA study of Clostridioides difficile infection identified Cd40 among nine core genes linked to toxin A/toxin B-associated inflammatory and immune networks, supporting a role for CD40 in the host transcriptional response to CDI 42230843Jun.

What Changes, What Holds

1. CD40 blockade looks insufficient as a stand-alone strategy for some autoimmune T-cell disease settings
NEW DIRECTION Recent comparative and mechanistic work does not displace CD40’s established role as an immune costimulatory target, but it does narrow expectations for what CD40 inhibition can accomplish. In generalized myasthenia gravis it sits among several active immune-directed options rather than emerging as a clear leader 42467874Jul, and iscalimab’s limited effect on autoreactive effector and naïve alloreactive CD4 T-cell responses suggests that CD40 blockade alone may not deliver durable control in type 1 diabetes or other T-cell–driven diseases 42284279Jun.

2. CD40 signaling now looks important for maintaining local antitumor immune niches, not just broadly activating APCs
NEW DIRECTION The established account already places CD40 on antigen-presenting cells and links agonism to APC maturation, but these studies extend that biology into the tumor microenvironment and show a more specific structural role. CD40 activity in mature cDC1 cells appears to help sustain tertiary lymphoid structures, T follicular helper pools, germinal centers, and tumor-specific IgG 42462020Jul, while agonist combinations in pancreatic cancer and EpCAM-directed bispecific targeting reinforce CD40 as a context-dependent immune amplifier rather than a uniformly effective monotherapy 41935073Apr41989931Apr.

3. Human genetic and disease-association data now connect CD40 to lymphoma risk and immune-mediated traits
NEW DIRECTION These findings add disease-association evidence that the Overview does not cover, without overturning CD40’s immune-regulatory baseline. Genetically predicted CD40 levels were linked to lower ADHD risk 42216364May, CD40 was prioritized as a candidate target in Hodgkin lymphoma 41859349Mar, and PD-1 blockade–associated B-cell lymphomas showed CD40-linked proliferative signaling 42148884May. Together they suggest CD40 may mark or mediate disease susceptibility in settings beyond classic APC activation.

4. CD40 also appears in infection-response networks, broadening its disease footprint beyond cancer and autoimmunity
NEW DIRECTION The host-response analysis of Clostridioides difficile infection places Cd40 in inflammatory transcriptional programs tied to toxin-associated disease 42230843Jun. That does not challenge the established immune-regulatory role; it extends it into infectious inflammation and supports CD40 as part of a wider response network rather than a cancer- or autoimmunity-only target. The main implication is breadth, not a revised mechanism.

Overview update candidates: CD40’s role in maintaining tertiary lymphoid structures in tumors; limited efficacy of CD40 blockade alone in some T-cell–mediated autoimmune settings; genetic and disease-association links to lymphoma and ADHD; involvement in Clostridioides difficile host-response networks.